UroGen Pharma Ltd.
Financials
Valuation Metrics
UroGen Pharma Ltd.'s Market Cap is $1.68B. At end of 2025 it was $1.15B. Ranked #2135 of 3,118 in US market (top 68%), #827 of 1,474 on NASDAQ (top 56%), #152 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.68B | US#2,135/3,118 Sec#152/265 |
| Revenue | $189M | US#2,559/3,118 Sec#111/265 |
| Net Income | $-98M | US—/3,118 Sec—/265 |
| Total Assets | $253M | US#2,938/3,118 Sec#225/265 |
| Net Assets | $-132M | US#2,962/3,118 Sec#251/265 |
| Employees | 300 | US#2,406/3,118 Sec#109/265 |
| Value | ||
| P/S | 8.88x | US#2,632/3,118 Sec#107/265 |
| FCF Yield | -9.49% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROA | -38.65% | US#2,935/3,118 Sec#187/265 |
| Op. Margin | -35.32% | US#2,629/3,118 Sec#106/265 |
| Revenue Growth | 100.27% | US#96/3,118 Sec#34/265 |
| Financial Health | ||
| Total Debt | $196M | US#2,240/3,118 Sec#96/265 |
| FCF | $-159M | US#2,727/3,118 Sec#186/265 |
| Cash | $79M | US#2,348/3,118 Sec#192/265 |
| Current Ratio | 3.80x | US#600/3,118 Sec#165/265 |
| Performance | ||
| 1Y Return | 68.05% | US#342/3,118 Sec#62/265 |
| 1M Return | -16.91% | US#2,785/3,118 Sec#223/265 |
| From 52W High | -32.30% | US#2,180/3,118 Sec#148/265 |
| 1Y MDD | -42.22% | US#2,026/3,118 Sec#129/265 |
| Trading | ||
| Volume | 1,840,219 shares | US#1,503/3,118 Sec#138/265 |
| Trading Value | $62M | US#1,582/3,118 Sec#114/265 |
| Per Share | ||
| EPS | $-2.00 | US—/3,118 Sec—/265 |
| BPS | $-2.72 | US—/3,118 Sec—/265 |
Company Info
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.